Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics-guided dose modifications of antidepressants.

Clinics in laboratory medicine - 1 Dec 2008

Seeringer Angela, Kirchheiner Julia

Abstract excerpt

The efficacy of a drug therapy is influenced by many different factors, such as age, weight, comorbidity, and comedication, which vary among patients, as do the fixed parameters of sex and genotype. Enzymes involved in drug metabolism are genetically polymorphic, meaning that their activities differ depending on certain genotypes. Drugs are metabolized slowly in individuals carrying a genetic polymorphism that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Cytochrome P-450 Enzyme System
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 19059066
DOI: 10.1016/j.cll.2008.05.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics-guided dose modifications of antidepressants.PMID 19059066Read ↗

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].Semantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.Semantic proximity Read ↗

Cytochrome P450 genotype-guided drug therapies: An update on current states.Semantic proximity Read ↗

Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.Semantic proximity Read ↗

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Semantic proximity Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.Semantic proximity Read ↗

Pharmacogenetics: From Bench to ByteSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.